Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Mining and visualizing large anticancer drug discovery databases.

Shi LM, Fan Y, Lee JK, Waltham M, Andrews DT, Scherf U, Paull KD, Weinstein JN.

J Chem Inf Comput Sci. 2000 Mar-Apr;40(2):367-79.

PMID:
10761142
2.

The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.

Koo HM, Gray-Goodrich M, Kohlhagen G, McWilliams MJ, Jeffers M, Vaigro-Wolff A, Alvord WG, Monks A, Paull KD, Pommier Y, Vande Woude GF.

J Natl Cancer Inst. 1999 Feb 3;91(3):236-44.

PMID:
10037101
3.

Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.

Bradshaw TD, Shi DF, Schultz RJ, Paull KD, Kelland L, Wilson A, Garner C, Fiebig HH, Wrigley S, Stevens MF.

Br J Cancer. 1998 Aug;78(4):421-9.

4.

Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.

Kohlhagen G, Paull KD, Cushman M, Nagafuji P, Pommier Y.

Mol Pharmacol. 1998 Jul;54(1):50-8.

PMID:
9658189
5.

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF.

Science. 1998 May 1;280(5364):734-7.

6.

Mining the NCI anticancer drug discovery databases: genetic function approximation for the QSAR study of anticancer ellipticine analogues.

Shi LM, Fan Y, Myers TG, O'Connor PM, Paull KD, Friend SH, Weinstein JN.

J Chem Inf Comput Sci. 1998 Mar-Apr;38(2):189-99.

PMID:
9538518
7.

2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.

Bradshaw TD, Wrigley S, Shi DF, Schultz RJ, Paull KD, Stevens MF.

Br J Cancer. 1998 Mar;77(5):745-52.

8.
9.

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA.

Anticancer Drug Des. 1997 Oct;12(7):533-41. Review. No abstract available.

PMID:
9365500
10.

Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.

Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE.

J Natl Cancer Inst. 1997 Oct 15;89(20):1505-15.

PMID:
9337347
11.

A protein expression database for the molecular pharmacology of cancer.

Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN.

Electrophoresis. 1997 Mar-Apr;18(3-4):647-53.

PMID:
9150955
12.

An information-intensive approach to the molecular pharmacology of cancer.

Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD.

Science. 1997 Jan 17;275(5298):343-9.

PMID:
8994024
13.

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, Zarbl H, Vande Woude GF.

Cancer Res. 1996 Nov 15;56(22):5211-6.

14.

Studies on the mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts.

Barchi JJ Jr, Cooney DA, Ahluwalia GS, Gharehbaghi K, Covey JM, Hochman I, Paull KD, Jayaram HN.

J Exp Ther Oncol. 1996 May;1(3):191-203.

PMID:
9414404
15.

Antitumor 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin.

Hamel E, Lin CM, Plowman J, Wang HK, Lee KH, Paull KD.

Biochem Pharmacol. 1996 Jan 12;51(1):53-9.

PMID:
8534268
16.

Azatoxin derivatives with potent and selective action on topoisomerase II.

Leteurtre F, Sackett DL, Madalengoitia J, Kohlhagen G, MacDonald T, Hamel E, Paull KD, Pommier Y.

Biochem Pharmacol. 1995 May 11;49(9):1283-90.

PMID:
7763310
17.

Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents.

van Osdol WW, Myers TG, Paull KD, Kohn KW, Weinstein JN.

J Natl Cancer Inst. 1994 Dec 21;86(24):1853-9.

PMID:
7990160
18.

Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.

Gharehbaghi K, Sreenath A, Hao Z, Paull KD, Szekeres T, Cooney DA, Krohn K, Jayaram HN.

Biochem Pharmacol. 1994 Oct 7;48(7):1413-9.

PMID:
7945441
20.

Design and synthesis of ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro.

Jurayj J, Haugwitz RD, Varma RK, Paull KD, Barrett JF, Cushman M.

J Med Chem. 1994 Jul 8;37(14):2190-7.

PMID:
8035426
21.

Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action.

Koutsoukos AD, Rubinstein LV, Faraggi D, Simon RM, Kalyandrug S, Weinstein JN, Kohn KW, Paull KD.

Stat Med. 1994 Mar 15-Apr 15;13(5-7):719-30.

PMID:
8023045
22.

Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.

Gharehbaghi K, Paull KD, Kelley JA, Barchi JJ Jr, Marquez VE, Cooney DA, Monks A, Scudiero D, Krohn K, Jayaram HN.

Int J Cancer. 1994 Mar 15;56(6):892-9.

PMID:
7907081
23.

Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.

Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y.

Biochem Pharmacol. 1993 Jun 22;45(12):2449-56.

PMID:
8392342
24.

Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.

Kuo SC, Lee HZ, Juang JP, Lin YT, Wu TS, Chang JJ, Lednicer D, Paull KD, Lin CM, Hamel E, et al.

J Med Chem. 1993 Apr 30;36(9):1146-56.

PMID:
8387598
25.

In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Finlay GJ, Marshall E, Matthews JH, Paull KD, Baguley BC.

Cancer Chemother Pharmacol. 1993;31(5):401-6.

PMID:
8381721
26.

Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.

Hendriks HR, Plowman J, Berger DP, Paull KD, Fiebig HH, Fodstad O, Dreef-van der Meulen HC, Henrar RE, Pinedo HM, Schwartsmann G.

Ann Oncol. 1992 Nov;3(9):755-63.

PMID:
1450065
27.

Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells.

Jayaram HN, Gharehbaghi K, Jayaram NH, Rieser J, Krohn K, Paull KD.

Biochem Biophys Res Commun. 1992 Aug 14;186(3):1600-6.

PMID:
1354960
28.
29.

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al.

Cancer Res. 1992 Jun 1;52(11):3029-34.

31.

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR.

J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8.

PMID:
2359137
32.

Computer-assisted structure--antileukemic activity analysis of purines and their aza and deaza analogs.

Narayanan VL, Nasr M, Paull KD.

Prog Drug Res. 1990;34:319-41. Review. No abstract available.

PMID:
2236568
33.

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR.

J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92.

PMID:
2738938
34.

Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.

Plowman J, Harrison SD, Dykes DJ Jr, Paull KD, Narayanan VL, Tobol HK, Martin J, Griswold DP Jr.

Cancer Res. 1989 Apr 15;49(8):1909-15.

35.

Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR.

Cancer Res. 1988 Sep 1;48(17):4827-33.

36.

Preclinical antitumor activity of batracylin (NSC 320846).

Plowman J, Paull KD, Atassi G, Harrison SD Jr, Dykes DJ, Kabbe HJ, Narayanan VL, Yoder OC.

Invest New Drugs. 1988 Sep;6(3):147-53.

PMID:
3192381
37.

Development of human tumor cell line panels for use in disease-oriented drug screening.

Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG, Boyd MR.

Prog Clin Biol Res. 1988;276:265-86. Review. No abstract available.

PMID:
3051021
38.
39.

Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.

Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD.

Cancer Treat Rep. 1986 May;70(5):631-5.

PMID:
3708611
40.

Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

Dexter DL, Hesson DP, Ardecky RJ, Rao GV, Tippett DL, Dusak BA, Paull KD, Plowman J, DeLarco BM, Narayanan VL, et al.

Cancer Res. 1985 Nov;45(11 Pt 1):5563-8.

41.

Computer-assisted structure--anticancer activity correlations of carbamates and thiocarbamates.

Nasr M, Paull KD, Narayanan VL.

J Pharm Sci. 1985 Aug;74(8):831-6.

PMID:
4032265
42.

5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agent.

Brewer AD, Minatelli JA, Plowman J, Paull KD, Narayanan VL.

Biochem Pharmacol. 1985 Jun 1;34(11):2047-50. No abstract available.

PMID:
3839128
43.
44.

Computer-assisted structure-activity correlations.

Nasr M, Paull KD, Narayanan VL.

Adv Pharmacol Chemother. 1984;20:123-90. Review.

PMID:
6398967
45.

2-beta-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases.

Robins RK, Srivastava PC, Narayanan VL, Plowman J, Paull KD.

J Med Chem. 1982 Feb;25(2):107-8. No abstract available.

PMID:
7057413
46.

Antineoplastic agents. 76. The sea urchin Strongylocentrotus droebachiensis.

Pettit GR, Hasler JA, Paull KD, Herald CL.

J Nat Prod. 1981 Nov-Dec;44(6):701-4.

PMID:
7334385
47.

Some substituted naphthazarins as potential anticancer agents.

Paull KD, Zee-Cheng RK, Cheng CC.

J Med Chem. 1976 Feb;19(2):337-9.

PMID:
1061817
48.

Experimental antileukemic agents. Coralyne, analogs, and related compounds.

Zee-Cheng KY, Paull KD, Cheng CC.

J Med Chem. 1974 Mar;17(3):347-51. No abstract available.

PMID:
4811233
49.

A facile synthesis of 4-substituted 3a,4,5,9b-tetrahydrobenz(e)isoindolines.

Paull KD, Cheng CC.

J Org Chem. 1972 Oct 20;37(21):3374-6. No abstract available.

PMID:
5072905
50.

Synthesis of 9-(3,4-dimethoxyphenoxy)-1,2,10-trimethoxyaporphine.

Paull KD, Engle RR, Twanmoh LM, Wood HB Jr, Driscoll JS.

J Pharm Sci. 1972 Sep;61(9):1481-3. No abstract available.

PMID:
5068959

Supplemental Content

Loading ...
Support Center